Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Tobacco Use Disorder 1Smoking Cessation 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lung Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Behavior 1

Interventions

Cyclophosphamide 409Methotrexate 246Cytarabine 231Vincristine 188fludarabine phosphate 172Dexamethasone 169fludarabine 143Etoposide 143Peripheral Blood Stem Cell Transplantation 136Filgrastim 132Whole-Body Irradiation 116Mycophenolic Acid 115Busulfan 112Doxorubicin 109Tacrolimus 106Mercaptopurine 106Cyclosporine 95Radiotherapy 93Melphalan 93Rituximab 90pegaspargase 88Prednisone 85Asparaginase 84Daunorubicin 82Granulocyte Colony-Stimulating Factor 74blinatumomab 72Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Risk Factors × Clear all
NCT05029531 2024-06-28

Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 3 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡